JANUX THERAPEUTICS INC (JANX:NASDAQ)
$13.7 -0.04 (-0.2911%)
Analysed JANUX THERAPEUTICS INC (JANX:NASDAQ) News Sources
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
28-04-2026
biopharmadive.com
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%
07-05-2026
yahoo.com
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
07-05-2026
yahoo.com
Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates
07-05-2026
yahoo.com
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
23-05-2026
fool.com
What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch
23-05-2026
fool.com
Here's Why You Should Add JANX Stock to Your Portfolio Now
26-05-2026
yahoo.com
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
28-05-2026
yahoo.com
VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC
28-05-2026
yahoo.com
Akari Therapeutics Highlights 1st ASCO Abstract Acceptance
28-05-2026
yahoo.com
What is the current price of JANUX THERAPEUTICS INC (JANX:NASDAQ)?
The current price of JANUX THERAPEUTICS INC (JANX:NASDAQ) is $13.7.
JANUX THERAPEUTICS INC (JANX:NASDAQ) absolute price change since previous trading day?
The absolute price change of JANUX THERAPEUTICS INC (JANX:NASDAQ) since the previous trading day is $-0.04.
JANUX THERAPEUTICS INC (JANX:NASDAQ) percentage price change since previous trading day?
The percentage price change of JANUX THERAPEUTICS INC (JANX:NASDAQ) since the previous trading day is -0.2911%.
What is the most recent average sentiment score for JANUX THERAPEUTICS INC (JANX:NASDAQ)?
The most recent average sentiment score for JANUX THERAPEUTICS INC (JANX:NASDAQ) is 66 out of 100.
What is the most recent average sentiment for JANUX THERAPEUTICS INC (JANX:NASDAQ)?
The most recent sentiment for JANUX THERAPEUTICS INC (JANX:NASDAQ) is .
SEC-8K** Filing Available For JANUX THERAPEUTICS INC (JANX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.